AXA IM Prime Impact Master Fund I SCA SICAV-RAIF - Dec 31, 2022 Form 5 Insider Report for REVELATION BIOSCIENCES, INC. (REVB)

Role: Former 10% Owner
Signature: /s/ Mirko Dietz Board Member, AXA IM Prime Impact GP S.a.r.l
Stock symbol: REVB
Transactions as of: Dec 31, 2022
Transactions value $: $0
Form type: 5
Date filed: 2/14/2023, 11:28 AM

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	REVB	Common stock	Other	$0	+1.96M		$0.00	1.96M	Jan 10, 2022	Direct	F1, F2, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

AXA IM Prime Impact Master Fund I SCA SICAV-RAIF is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	On January 10, 2022, Petra Acquisition, Inc. consummated a business combination with the old Revelation Biosciences, Inc., and the reporting persons became the holders of publicly traded shares of the Common Stock of the new Revelation Biosciences, Inc., pursuant to a registration statement
F2	The following parties may be deemed to have the power to vote and direct the disposition of the shares of Common Stock owned by AXA IM Prime Impact Master Fund ISCA SICAV-RAIF (the "Fund"):(a) the Fund owns the shares of Common Stock reported herein, (b) the general partner of the Fund, AXA IM Prime Impact GP S.a.r.l, has appointed AXA Investment Managers Paris S.A. ("AIFM") as the alternative investment fund manager of the Fund to undertake all functions required of an external alternative investment fund manager, (c) the Fund with the consent of AIFM and duly represented by its general partner, AXA IM Prime Impact GP S.a.r.l, has also entered into a delegated portfolio management agreement with AIFM and AXA Investment Managers UK Ltd. ("AXA IM UK") in order to appoint AXA IM UK to act as the portfolio manager of the Fund, (d) AXA Investment Managers S.A. is the sole shareholder of AIFM and AXA IM UK, and (e) AXA S.A. is the controlling shareholder of AXA IM SA.
F3	The reporting persons do not believe that they constitute a "group" within the meaning of Rule 13d-5 under the Securities Exchange Act of 1934, as amended, and they do not believe that they are otherwise required to attribute to each other the beneficial ownership of the securities reported herein held by them or by any persons or entities for whom or for which AIFM or AXA IM UK provides investment management services. Each of the reporting persons also disclaims beneficial ownership of these securities except to the extent of that person's pecuniary interest therein.
F4	On July 28, 2022, the issuer closed a public offering, and, as a result of the dilutive effect of the public offering, the reporting persons ceased to beneficially own more than 10% of the issuer's Common Stock outstanding as of the close of business on July 28, 2022.